An experimental drug
has shown encouraging results in treating advanced breast cancer in an
early clinical trial, pharmaceutical giant Pfizer reported Sunday.
Pfizer,
the world's second largest drugmaker, said the drug prevented breast
cancer from worsening for 20.2 months in a trial involving 165 patients.
Current medications do so for 10.2 months. The drug, known as
palbociclib, is among a new class of cancer drugs that target specific
proteins to block tumors.
The outcome wasn't
as positive as some initial results reported earlier in the tests, said
University of Michigan business professor Erik Gordon, who studies the
biomedical industry but isn't affiliated with the trial.
No comments:
Post a Comment